Monotherapy in patients with type 2 diabetes mellitus

키워드

참고문헌 (54)

1. UK Prospective Diabetes Study (UKPDS) Group., "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)", Lancet, 352, pp.837~853 (1998)
2. Holman RR, "10-Year follow-up of intensive glucose control in type 2diabetes", N Engl J Med, 359, pp.1577~1589 (2008)
3. Action to Control Cardiovascular Risk in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes", N Engl J Med, 358, pp.2545~2559 (2008)
4. ADVANCE Collaborative Group, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", N Engl J Med, 358, pp.2560~2572 (2008)
5. Duckworth W, "Glucose control and vascular complications in veterans with type 2 diabetes", N Engl J Med, 360, pp.129~139 (2009)
6. Ismail-Beigi F, "Individualizing glycemic targets in type 2diabetes mellitus: implications of recent clinical trials", Ann Intern Med, 154, pp.554~559 (2011)
7. Inzucchi SE, "Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes", Diabetes Care, 38, pp.140~149 (2015)
8. Look AHEAD Research Group, "Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes", N Engl J Med, 369, pp.145~154 (2013)
9. Pillay J, "Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis", Ann Intern Med, 163, pp.848~860 (2015)
10. Turner RC, "Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)", JAMA, 281, pp.2005~2012 (1999), UK Prospective Diabetes Study (UKPDS) Group
11. 고승현, "Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association", Diabetes and Metabolism Journal, 41(5), pp.337~348 (2017), 대한당뇨병학회[DOI]
12. The Korea National Diabetes Program (KNDP) Investigators., "Clinical Practice Guideline for the Prevention and Management of Diabetes in Korea" (2014), Medbook
13. Korean Diabetes Association., "2015 Treatment Guidelines for Diabetes", Korean Diabetes Association, ~ (2015)
14. American Diabetes Association., "8.Pharmacologic approaches to glycemic treatment", Diabetes Care, 40(Suppl 1), pp.S64~S74 (2017)
15. McGuire H, "Management of type 2diabetes in adults: summary of updated NICE guidance", BMJ, 353, pp.i1575~ (2016)
16. International Diabetes Federation Guideline Development Group., "Global guideline for type 2 diabetes", Diabetes Res Clin Pract, 104, pp.1~52 (2014)
17. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, "Pharmacologic management of type 2 diabetes", Can J Diabetes, 37(Suppl 1), pp.S61~S68 (2013)
18. Garber AJ, "Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm:2017 executive summary", Endocr Pract, 23, pp.207~238 (2017)
19. Bloomgarden ZT, "Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis", Diabetes Care, 29, pp.2137~2139 (2006)
20. Sherifali D, "The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis", Diabetes Care, 33, pp.1859~1864 (2010)
21. Monnier L, "Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:variations with increasing levels of HbA(1c)", Diabetes Care, 26, pp.881~885 (2003)
22. Bonora E, "Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes:the epidemiological evidence", Diabetologia, 44, pp.2107~2114 (2001)
23. Glucose tolerance and mortality: comparison of WHO, "Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe", Lancet, 354, pp.617~621 (1999)
24. UK Prospective Diabetes Study (UKPDS) Group., "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)", Lancet, 352, pp.854~865 (1998)
25. Goldberg RB, "Effect of longterm metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium", Circulation, 136, pp.52~64 (2017)
26. Bennett WL, "Comparative effectiveness and safety of medications for type 2 diabetes:an update including new drugs and 2-drug combinations", Ann Intern Med, 154, pp.602~613 (2011)
27. Chan JC, "Role of metformin in the initiation of pharmacotherapy for type 2diabetes: an Asian-Pacific perspective", Diabetes Res Clin Pract, 75, pp.255~266 (2007)
28. Maruthur NM, "Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis", Ann Intern Med, 164, pp.740~751 (2016)
29. Palmer SC, "Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis", JAMA, 316, pp.313~324 (2016)
30. 윤건호, "Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study", Diabetes and Metabolism Journal, 35(1), pp.26~33 (2011), 대한당뇨병학회
31. Aroda VR, "Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study", J Clin Endocrinol Metab, 101, pp.1754~1761 (2016)
32. Kim YG, "Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians:a systematic review and meta-analysis", Diabetologia, 56, pp.696~708 (2013)
33. Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
34. White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
35. Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
36. Abbas AS, "Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition:a meta-analysis of randomized controlled cardiovascular outcome trials", Diabetes Obes Metab, 18, pp.295~299 (2016)
37. Kongwatcharapong J, "Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials", Int J Cardiol, 211, pp.88~95 (2016)
38. Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
39. Monami M, "Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials", Acta Diabetol, 54, pp.19~36 (2017)
40. Kaku K, "Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from EMPA-REG OUTCOME((R))", Circ J, 81, pp.227~234 (2017)
41. Neal B, "Canagliflozin and cardiovascular and renal events in type 2 diabetes", N Engl J Med, 377, pp.644~657 (2017)
42. Varvaki Rados D, "The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials", PLoS Med, 13, pp.e1001992~ (2016)
43. 김세영, "한국인 제2형 당뇨병환자에서 Mitiglinide의 유효성 및 안전성 평가:전향적, 무작위배정, 다기관 비교 3상 시험", Diabetes and Metabolism Journal, 31(2), pp.163~174 (2007), 대한당뇨병학회
44. Joshi SR, "Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review", Expert Opin Pharmacother, 16, pp.1959~1981 (2015)
45. Dormandy JA, "Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial", Lancet, 366, pp.1279~1289 (2005)
46. Lincoff AM, "Pioglitazone and risk of cardiovascular events in patients with type 2diabetes mellitus: a meta-analysis of randomized trials", JAMA, 298, pp.1180~1188 (2007)
47. Chiasson JL, "The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial", Ann Intern Med, 121, pp.928~935 (1994)
48. Hoffmann J, "Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study", Diabetes Care, 17, pp.561~566 (1994)
49. Holman RR, "A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)", Diabetes Care, 22, pp.960~964 (1999)
50. Black C, "Meglitinide analogues for type 2 diabetes mellitus", Cochrane Database Syst Rev, (2), pp.CD004654~ (2007)
51. Chin SO, "Hypoglycemia is associated with dementia in elderly patients with type 2diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort", Diabetes Res Clin Pract, 122, pp.54~61 (2016)
52. Rhee SY, "Hypoglycemia and medical expenses in patients with type 2 diabetes mellitus:an analysis based on the Korea National Diabetes Program Cohort", PLoS One, 11, pp.e0148630~ (2016)
53. 차선아, "Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes", Diabetes and Metabolism Journal, 40(3), pp.202~210 (2016), 대한당뇨병학회[DOI]
54. 윤재승, "Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus", Diabetes and Metabolism Journal, 40(6), pp.423~432 (2016), 대한당뇨병학회[DOI]

관련 논문AI추천